Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study
Journal of Gastrointestinal Oncology · 2024-04 · 15 (2) · 612-629
DOI: 10.21037/jgo-24-98 ↗Kurz gefasst
Kohortenstudie in der Zeitschrift Journal of Gastrointestinal Oncology, 2024-04. Verfasst von Rong-Rong Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology Gastroenterology and Urology, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central…. Die Arbeit wurde bisher 4-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Background
Several studies demonstrated trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) had better efficacy than the monotherapy of TAS-102 in refractory metastatic colorectal cancer (mCRC). However, it remains unclear whether Chinese population can benefit from this combination or not. Hence, we conducted this retrospective cohort study to compare the efficacy and safety between TAS-102 plus BEV with TAS-102 monotherapy in refractory mCRC.
Methods
This retrospective cohort study enrolled patients (any age) with refractory mCRC from Hunan Cancer Hospital. The main inclusion criteria were histopathologically and/or radiographically confirmed refractory mCRC, World Health Organization (WHO) performance status of 0 to 2, adequate organ function, and initial treatment of TAS-102 with or without BEV between November 2020 and October 2022. Previous therapy with fruquintinib or regorafenib was allowed but not mandatory. Baseline demographic and clinical characteristics were collected appropriately. Every 2 or 3 treatment cycles, the patients were assessed by computed tomography (CT) scans and clinical assessments until disease progression or loss to follow-up. The National Cancer Institute Common Terminology Criteria for Adverse Events 5.0 (NCI-CTCAE 5.0) were presented as n (%). The primary endpoint was investigator-evaluated overall survival (OS). As this is a retrospective cohort study, sample size calculation was not performed. Eligible patients would be enrolled as many as possible.
Results
A total of 90 patients were enrolled, including 58 patients who received TAS-102 plus BEV and another 32 patients who received TAS-102 monotherapy. The known baseline characteristics were comparable (P
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Medical Oncology Gastroenterology and Urology, Hunan Cancer Hospital, Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China.
- Department of Surgical Sciences, Uppsala University Hospital, Uppsala, Sweden.
ORCID-Profile: Rong-Rong Li
Zitieren
APA
Li, R. R., Zhou, H. J., Zeng, D. Y., Jiang, S. F., Liu, W., Frühling, P., & Liu, Z. Y. (2024). Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study. Journal of Gastrointestinal Oncology, 15(2), 612-629. https://doi.org/10.21037/jgo-24-98
Vancouver
Li RR, Zhou HJ, Zeng DY, Jiang SF, Liu W, Frühling P, et al. Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study. Journal of Gastrointestinal Oncology. 2024;15(2):612-629. doi:10.21037/jgo-24-98
BibTeX
@article{Li2024,
author = {Li, Rong-Rong and Zhou, Hui-Jun and Zeng, De-Yu and Jiang, Shao-Feng and Liu, Wu and Frühling, Petter and Liu, Zhen-Yang},
title = {Efficacy and safety of trifluridine/tipiracil plus bevacizumab versus trifluridine/tipiracil monotherapy for refractory metastatic colorectal cancer: a retrospective cohort study},
journal = {Journal of Gastrointestinal Oncology},
year = {2024},
volume = {15},
number = {2},
pages = {612--629},
doi = {10.21037/jgo-24-98}
}
EUVIMED